诺坎塔里丁对肝细胞癌的药理学机制
Zhong-Ming Qian1,2, Yun-Jin Chen1,2, Yu-Xin Bao3
1Institute of Translational and Precision Medicine, Department of Neurology, Affiliated Hospital, Nantong University No. 19 Qi Xiu Road, Nantong 226001, Jiangsu, China.
American journal of cancer research
|December 7, 2023
概括
诺坎塔里丁 (NCTD) 通过诱导细胞死亡,抑制细胞增殖和转移,有效治疗肝细胞癌 (HCC). 它的机制涉及调节关键基因和信号通路,为HCC提供了有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 肝细胞癌 (HCC) 是一个主要的全球健康问题.
- 诺坎塔里丁 (NCTD) 是中国批准的抗癌药物,特别研究用于HCC治疗.
研究的目的:
- 审查最近在HCC治疗中NCTD应用的进展.
- 阐明NCTD对HCC的药理机制.
主要方法:
- 审查关于NCTD对HCC的影响的研究.
- 分析NCTD对细胞过程的影响,如线粒体停止,增殖,转移和细胞死亡.
- 调查NCTD的分子目标和信号通路.
主要成果:
- 在HCC中,NCTD诱导了线粒性止,抗扩散,抗转移,亡和细胞毒性自.
- 机制包括ISG15,MMP-9,u-PA,Mcl-1和监管T细胞的下调.
- 通过对FAM46C,miR-214,p21Cip1/Waf1和CDC25C进行上调,同时抑制c-Met-mTOR和JAK/STAT3通路.
结论:
- 通过多种分子途径,NCTD表现出多方面的抗HCC特性.
- 作为肝细胞癌的治疗剂,NCTD显示出显著的潜力.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.2K
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
795
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
168
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
168
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K